Colorectal Cancer Biomarkers

Publication Date: February 6, 2017

Key Points

Key Points

Molecular testing to select targeted and conventional therapies for patients with colorectal cancer (CRC) has been the focus of a number of recent studies and is becoming standard practice for management of patients with CRC.

Current evidence-based recommendations for the molecular testing of CRC tissues to guide EGFR-targeted therapies and conventional chemotherapy regimens were developed through collaboration of four societies: American Society for Clinical Pathology (ASCP), College of American Pathologists (CAP), Association for Molecular Pathology (AMP), and American Society of Clinical Oncology (ASCO).

Diagnosis

Diagno...

...ctal carcinoma patients being considered for...


BRAF p.V600 (BRAF c. 1799 (p.V600)...


...mutational analysis should be performed in defi...


...d order mismatch repair status testing in patients...


...s insufficient evidence to recommend BRAF...


...insufficient evidence to recommend PIK...


...is insufficient evidence to recommend PTEN analy...


...tatic or recurrent colorectal carcinoma ti...


...ormalin fixed paraffin embedded tissue is an acc...


Laboratories must use validated colore...


...rmance of molecular biomarker testing fo...


...tories must validate the performance o...


...oratories must provide clinically a...


...IHC biomarker testing in colorectal carci...


...ries should establish policies to ensure effic...


...of the patient’s medical team,...


...atories that require send out of test...


...ts must evaluate candidate specimens...


...uld use colorectal carcinoma molecular b...


...lorectal carcinoma molecular biomarker r...


...orectal carcinoma molecular biomarker test...


...aboratories must incorporate colorecta...


...Outcomes of RAS Mutations and Anti...


...2. Concordance Rates Between Primary and...